Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siremadlin + Ribociclib in Liposarcoma
NCT02343172Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of siremadlin and ribociclib in Liposarcoma, sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities, Exposure to HDM201 and LEE011 as measured by AUC 0-24h and 1 more. Started Mar 2015; status: completed.
02
Drugs
siremadlinribociclib
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT02343172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343172.